Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use

1. A method for treating a disease, comprising administering a therapeutically effective dose of a pharmaceutical composition to a subject suffering from a disease, the pharmaceutical composition comprises one or more aptamer-mRNA conjugates, wherein each aptamer-mRNA conjugate comprises:

an aptamer component that binds a membrane associated protein on a target cell; and

an mRNA component that is expressed by the target cell,

wherein the mRNA component is an mRNA molecule.

2. The method of claim 1 , wherein the disease is a cancer.

3. The method of claim 2 , wherein the cancer is bone cancer, bladder cancer, brain cancer, breast cancer, cancer of the urinary tract, carcinoma, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, hepatocellular cancer, liver cancer, lung cancer, lymphoma (B cell and T cell) and leukemia, melanoma, ovarian cancer, pancreatic cancer, pituitary cancer, prostate cancer, rectal cancer, renal cancer, sarcoma, testicular cancer, thyroid cancer, or uterine cancer.

4. The method of claim 1 , wherein the disease is a chronic viral infection.

5. The method of claim 4 , wherein the chronic viral infection is hepatitis, papillomavirus, herpes simplex virus (HSV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), Smallpox virus, and human or simian immunodeficiency virus (HIV/SHIV).

6. The method of claim 1 , wherein the disease is a genetic disorder.

7. The method of claim 6 , wherein the genetic disorder is muscular dystrophy, hemophilia, Huntington's disease, alpha-1 antitrypsin deficiency, Alzheimer's disease, various forms of breast cancer (e.g., BRCA1), cystic fibrosis, galactosemia, congenital hyperthyroidism, maple syrup urine disease, neurofibromatosis I, phenylketonuria, sickle cell disease, and Smith-Lemli-Opitz (SLO-RSH) syndrome, familial hypercholesterolemia, polycystic kidney disease, hereditary spherocytosis, Marfan syndrome, Tay-Sachs disease, mucoplysacchariddoses, and glycogen storage diseases.

8. The method of claim 1 , wherein the membrane associated protein is CD4, CD19, DC-SIGN/CD209, HIV envelope glycoprotein gp120, CCR5, EGFR/ErbB1, EGFR2/ErbB2/HER2, EGFR3/ErbB3, EGFR4/ErbB4, EGFRvIII, Transferrin Receptor, PSMA, VEGF, VEGF-2, CD25, CD11a, CD33, CD20, CD3, CD52, CEA, TAG-72, LDL receptor, insulin receptor, megalin receptor, LRP, mannose receptor, P63/CKAP4 receptor, arrestin, ASGP, CCK-B, HGFR, RON receptor, FGFR, ILR, AFP, CA125/MUC16, PDGFR, stem cell factor receptor, colony stimulating factor-1 receptor, integrins, TLR, BCR or BAFF-R.

9. The method of claim 1 , wherein the mRNA component is a therapeutic agent.

10. The method of claim 9 , wherein the therapeutic agent is a cytotoxin, an enzyme, or an antibody or functional fragment thereof.

11. The method of claim 1 , wherein the mRNA component is a fluorescent or bioluminescent protein.